Loading...
Please wait, while we are loading the content...
Similar Documents
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Dreger, Peter Sureda, Anna Ahn, Kwang Woo Eapen, Mary Litovich, Carlos Finel, Hervé Boumendil, Ariane Gopal, Ajay K. Herrera, Alex F. Schmid, Christoph Díez-Martín, José Luís Fuchs, Ephraim Joseph Bolaños-Meade, Javier Gooptu, Mahasweta Malki, Monzr M. Al Castagna, Luca Ciurea, Stefan O. Dominietto, Alida Blaise, Didier Ciceri, Fabio Tischer, Johanna Corradini, Paolo Montoto, Silvia Robinson, Stephen Gülbaş, Zafer Hamadani, Mehdi |
| Copyright Year | 2019 |
| Abstract | This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis in MSD was limited to calcineurin inhibitor (CNI)-based approaches without in vivo TCD, while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients (haplo, 132; MSD, 525; MUD TCD+, 403; and MUD TCD-, 378) were included. Patients with haplo donors were significantly older, had a better performance status and had more frequently received total body irradiation-based conditioning regimens and bone marrow grafts than MSD and MUD TCD+ or TCD-. 3-year OS, PFS, NRM and relapse/progression incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly different from outcomes of matched donor transplants on multivariate analyses. Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD compared with MSD, MUD TCD+/TCD-. NMC/RIC haplo-HCT with PTCy seems to be a valuable alternative for patients with DLBCL considered for allo-HCT but lacking a matched donor. |
| Starting Page | 360 |
| Ending Page | 369 |
| Page Count | 10 |
| File Format | PDF HTM / HTML |
| DOI | 10.1182/bloodadvances.2018027748 |
| PubMed reference number | 30723110 |
| Journal | Medline |
| Volume Number | 3 |
| Issue Number | 3 |
| Alternate Webpage(s) | https://air.unimi.it/retrieve/handle/2434/622000/1160989/Dreger%20-%20Blood%20Advances%202019.pdf |
| Alternate Webpage(s) | https://doi.org/10.1182/bloodadvances.2018027748 |
| Journal | Blood advances |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
